Clinical trials: Brain Diseases, Metabolic
Abdominal Obesity, Growth Hormone Deficiency
Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese
Obesity, a condition that occurs when a person has too much body fat, affects about 31% of people in the United States. It is associated with increased risk of diabetes, high blood pressure, high cholesterol, and cardiovascular…
- Trial name
- NCT00675506
- Testing
- Growth hormone releasing hormone (GHRH) 1-44
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Primary Progressive Aphasia
Communication Bridge 2
This study will use a randomized controlled trial design to evaluate the effect of two evidence-based treatments for adults with mild Primary Progressive Aphasia (PPA).
- Trial name
- CB2 (NCT03371706)
- Testing
- Communication Bridge™, Evidence-Based Impairment Focused
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- University of Chicago
Acute Myocardial Infarction, Diabetes Mellitus
Association of Long-term Conditions With Survival Following Heart Attack in England and Wales
This study aims to determine the extent to which pre-existing long-term conditions are associated with survival following a heart attack (acute myocardial infarction) using observational data from the UK's national heart attack…
- Conditions
- Acute Myocardial Infarction, Diabetes Mellitus, Peripheral Vascular Disease, Chronic Heart Failure
- Trial name
- NCT03037255
- Testing
- long term conditions
- Volunteers
- 693,633 people
- Sponsor
- Marlous Hall
Wilson Disease
An Exploratory Study to Evaluate the Tolerability and Safety of MWAV201 in Subjects With Wilson Disease
The primary objective of this study is to evaluate the tolerability and safety of MWAV201 in patients with Wilson disease.
- Trial name
- NCT06663878
- Testing
- MWAV201
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Neurodegenerative Diseases
Continuation Study for Latozinemab
Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study
- Trial name
- NCT06111014
- Testing
- Latozinemab
- Where
- 18 sites in United States, Belgium and 8 more
- Volunteers
- 17 people
- Sponsor
- Alector Inc.
Gaucher Disease
Validating a New Severity Score System for Adults With Type 1 Gaucher Disease (GD1)
With the participation of an international consortium of investigators, the investigators will evaluate the validity of a new severity score system called DS3 for adult patients with Gaucher disease.
- Trial name
- NCT01136304
- Testing
- Imiglucerase
- Where
- 2 sites in United States
- Volunteers
- 173 people
- Sponsor
- University Research Foundation for Lysosomal Storage Diseases, Inc.
Stroke, Obesity
Secondary Prevention of Stroke Through Non-drug Therapeutic Weight Reduction
SCENARIO is a trial to investigate the role of non-drug weight reduction in secondary prevention of stroke. It is a single-blinded, randomized, controlled multicentre trial with two arms.
- Trial name
- SCENARIO (NCT01721538)
- Testing
- Weight reduction program, Lecture on healthy nutrition
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Philipps University Marburg
Gaucher Disease
Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase
This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase (Cerezyme®) enzyme replacement therapy.
- Trial name
- NCT00712348
- Testing
- Taliglucerase alfa
- Where
- 10 sites in United States, Australia and 4 more
- Volunteers
- 31 people
- Sponsor
- Pfizer
Early Onset Alzheimer Disease, Frontotemporal Dementia
RHAPSODY-plus: Online Counseling for Family Caregivers of Patients With Young Onset Dementia
The RHAPSODY-plus project consists of two parts. In a first step carers of people with young onset dementia (YOD; onset before the age of 65) have the opportunity to use the RHAPSODY online program (Kurz et al., 2016) to inform…
- Trial name
- RHAPSODY-plus (NCT03923517)
- Testing
- RHAPSODY online program and MEET online sessions
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Technical University of Munich
Hypoparathyroidism, Pseudo Hypoparathyroidism
QoL and Cognitive Function in Patients With Hypoparathyroidism
Hypoparathyroidism (HypoPT) is a disease with inadequate production of parathyroid hormone (PTH) from the parathyroid glands leading to hypocalcemia.
- Trial name
- MR-hypoPT (NCT04569604)
- Testing
- MRI scans, Neuro cognitive tests, Questionnaires on Quality of Life
- Where
- Denmark
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Diabetes, Dementia
Deprescribing of Diabetes Regimens in Long Term Care Residents With Alzheimer's
Objectives To 1) examine the ability of the STRIDE (Simplification of Treatment Regimens and Individualized Diabetes Education) educational program to increase deprescribing of high hypoglycemia risk glucose-lowering medications…
- Conditions
- Diabetes, Dementia, Hypoglycemia; Drug
- Trial name
- NCT05535478
- Testing
- STRIDE
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Joslin Diabetes Center
Thiamine Deficiency, Thiamine Deficiency; Sequelae
Prevalence of Thiamine Deficiency in Hospitalized Non-Alcoholic Veterans
Thiamine micronutrient deficiency (TD) can cause a variety of non-specific symptoms and leads to several thiamine deficiency disorders such as heart failure, polyneuropathy, Wernicke's Encephalopathy and generalized weakness and…
- Trial name
- NCT05480943
- Testing
- Thiamine repletion
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- VA Office of Research and Development
Hematological Malignancies
Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide
The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitors (HTLP)) injection to accelerate immune reconstitution after haploidentical hematopoietic stem cell transplantation…
- Trial name
- NCT05768035
- Testing
- Allogeneic T cell progenitors, cultured ex-vivo
- Where
- 4 sites in France
- Volunteers
- 40 people
- Sponsor
- Smart Immune SAS
Amyotrophic Lateral Sclerosis
Blood-Brain Barrier Opening Using MR-Guided Focused Ultrasound in Patients With Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate the safety, tolerability, and feasibility of Blood-Brain Barrier (BBB) opening using transcranial MRI-guided focused ultrasound in conjunction with an intravenous ultrasound contrast agent…
- Trial name
- NCT03321487
- Testing
- Blood-Brain Barrier opening with MRgFUS
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- InSightec
Depression, Depressive Disorder
Near-infrared Transcranial Laser Therapy in Subjects With Major Depressive Disorder
Major depressive disorder (MDD) is a leading cause of disability worldwide, and many patients do not achieve adequate benefit from current treatments.
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- ELATED-4 (NCT06934135)
- Testing
- Bilateral Near-Infrared Transcranial Photobiomodulation (tPBM)
- Where
- 2 sites in Peru
- Volunteers
- 50 people
- Sponsor
- NeuroThera DE
Proton Pump Inhibitor Adverse Reaction, Liver Cirrhosis
Proton Pump Inhibitors in Cirrhotic Patients
Proton pump inhibitors (PPIs) inappropriate use, in patients with cirrhosis, presents a significant clinical challenge. This study evaluates overprescription and misuse of PPIs in cirrhotic patients.
- Trial name
- NCT06384443
- Where
- Egypt
- Volunteers
- 1,000 people
- Sponsor
- National Liver Institute, Egypt
Fabry Disease
Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease
BIO-AGA-Fase III-001 is a Phase III, prospective, multicenter, open-label, single-group, baseline-controlled, switch over clinical trial to evaluate the efficacy and safety of AGA BETA BS in patients with FD already treated and…
- Trial name
- SMILE (NCT05843916)
- Testing
- Recombinant human alpha galactosidase A (agalsidase beta), Recombinant human alpha-galactosidase A (agalsidase beta)
- Where
- 5 sites in Argentina
- Volunteers
- 20 people
- Sponsor
- Bio Sidus SA
Vitamin/Nutritional Deficiency, Neurobehavioral Manifestations
Walnuts, Long-Chain Polyunsaturated Fatty Acids and Adolescent Brain Development
Background: Adolescence is an important period for brain development as a result of increased synaptic plasticity. Omega-3 polyunsaturated fatty acids (n-3 PUFAs) are essential nutrients for brain development and protection…
- Trial name
- WALNUTs (NCT02590848)
- Testing
- Walnut intake
- Where
- Spain
- Volunteers
- 730 people, healthy volunteers welcome
- Sponsor
- Barcelona Institute for Global Health
Hepatic Encephalopathy
Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis
Study RNLC3132 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE)…
- Trial name
- RED-C-3132 (NCT05297448)
- Testing
- Rifaximin SSD
- Where
- 188 sites in United States, Australia and 15 more
- Volunteers
- 517 people
- Sponsor
- Bausch Health Americas, Inc.
Hyponatremia
Tolvaptan for In-hospital Hyponatremia
Hyponatremia is a common electrolyte disorder encountered in hospitalized patients. A preliminary, observational, feasibility analysis finalized to assess retrospectively the incidence of hyponatremia (Serum sodium < 135 mEq/L)…
- Trial name
- INSERT (NCT01386372)
- Testing
- Tolvaptan, Standard therapy
- Where
- Italy
- Volunteers
- 3 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.